Variant Bio announced the launch of Inference on January 6, 2026, described as the world's first agentic AI genomic drug discovery platform.12
The platform integrates proprietary and public genetic/multi-omic data, processing hundreds of billions of genetic associations from tens of thousands of genome-wide association studies.123
Key AI features include Inference Agents for autonomous PhD-level analyses using Model Context Protocol (MCP), VB-Predict for molecular disease models, and VB-Atlas for gene-phenotype mappings.12
Built over seven years with over $100 million investment, it's now available to pharmaceutical partners, powering collaborations over $200 million.12
Supports secure upload of proprietary data and includes a benefit-sharing pledge for research communities.12
Underpins internal drug programs and partnerships, including a new kidney disease collaboration with Boehringer Ingelheim.347
Sources:
1. https://www.morningstar.com/news/pr-newswire/20260106sf56942/variant-bio-launches-inference-the-worlds-first-agentic-ai-genomic-drug-discovery-platform
2. https://www.prnewswire.com/news-releases/variant-bio-launches-inference-the-worlds-first-agentic-ai-genomic-drug-discovery-platform-302653399.html
3. https://longevity.technology/news/variant-bio-launches-agentic-genomic-drug-discovery-platform/
4. https://www.pharmalive.com/variant-bio-announces-discovery-collaboration-with-boehringer-ingelheim-for-kidney-disease/
7. https://www.indexbox.io/blog/variant-bio-launches-ai-drug-discovery-platform-and-partners-with-boehringer-ingelheim/